A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Cong Xue
No relevant relationships to disclose
Qitao Yu
No relevant relationships to disclose
Jian-ji Pan
No relevant relationships to disclose
Yuanlu Sun
No relevant relationships to disclose
Li Zhang
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Research Funding - Lilly; Pfizer